Literature DB >> 20833967

Dark chocolate receptors: epicatechin-induced cardiac protection is dependent on delta-opioid receptor stimulation.

Mathivadhani Panneerselvam1, Yasuo M Tsutsumi, Jacqueline A Bonds, Yousuke T Horikawa, Michelle Saldana, Nancy D Dalton, Brian P Head, Piyush M Patel, David M Roth, Hemal H Patel.   

Abstract

Epicatechin, a flavonoid, is a well-known antioxidant linked to a variety of protective effects in both humans and animals. In particular, its role in protection against cardiovascular disease has been demonstrated by epidemiologic studies. Low-dose epicatechin, which does not have significant antioxidant activity, is also protective; however, the mechanism by which low-dose epicatechin induces this effect is unknown. Our laboratory tested the hypothesis that low-dose epicatechin mediates cardiac protection via opioid receptor activation. C57BL/6 mice were randomly assigned to 1 of 10 groups: control, epicatechin, naloxone (nonselective opioid receptor antagonist), epicatechin + naloxone, naltrindole (δ-specific opioid receptor antagonist), epicatechin + naltrindole, norbinaltorphimine (nor-BNI, κ-specific opioid receptor antagonist), epicatechin + nor-BNI, 5-hydroxydecanoic acid [5-HD, ATP-sensitive potassium channel antagonist], and epicatechin + 5-HD. Epicatechin (1 mg/kg) or other inhibitors (5 mg/kg) were administered by oral gavage or intraperitoneal injection, respectively, daily for 10 days. Mice were subjected to 30 min coronary artery occlusion followed by 2 h of reperfusion, and infarct size was determined via planimetry. Whole heart homogenates were assayed for downstream opioid receptor signaling targets. Infarct size was significantly reduced in epicatechin- and epicatechin + nor-BNI-treated mice compared with control mice. This protection was blocked by naloxone, naltrindole, and 5-HD. Epicatechin and epicatechin + nor-BNI increased the phosphorylation of Src, Akt, and IκBα, while simultaneously decreasing the expression of c-Jun NH(2)-terminal kinase and caspase-activated DNase. All signaling effects are consistent with opioid receptor stimulation and subsequent cardiac protection. Naloxone, naltrindole, and 5-HD attenuated these effects. In conclusion, epicatechin acts via opioid receptors and more specifically through the δ-opioid receptor to produce cardiac protection from ischemia-reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833967      PMCID: PMC2993198          DOI: 10.1152/ajpheart.00073.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

1.  Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation.

Authors:  N Maulik; S Goswami; N Galang; D K Das
Journal:  FEBS Lett       Date:  1999-01-29       Impact factor: 4.124

2.  Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.

Authors:  Zhiping Cao; Lijuan Liu; Donna M Van Winkle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-01       Impact factor: 4.733

3.  ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection.

Authors:  R M Fryer; A K Hsu; G J Gross
Journal:  Basic Res Cardiol       Date:  2001-04       Impact factor: 17.165

4.  Flavonol glycosides from Aristeguietia discolor reduce morphine withdrawal in vitro.

Authors:  A Capasso; P Saturnino; F D Simone; R Aquino
Journal:  Phytother Res       Date:  2000-11       Impact factor: 5.878

5.  Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart.

Authors:  J J Schultz; A K Hsu; G J Gross
Journal:  J Mol Cell Cardiol       Date:  1997-08       Impact factor: 5.000

6.  Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening.

Authors:  Hemal H Patel; Lynda M Ludwig; Ryan M Fryer; Anna K Hsu; David C Warltier; Garrett J Gross
Journal:  FASEB J       Date:  2002-07-01       Impact factor: 5.191

8.  Flavonoids reduce morphine withdrawal in-vitro.

Authors:  A Capasso; S Piacente; C Pizza; L Sorrentino
Journal:  J Pharm Pharmacol       Date:  1998-05       Impact factor: 3.765

9.  Comparison of antioxidant activity and bioavailability of tea epicatechins with their epimers.

Authors:  Jin Ze Xu; Sai Ying Venus Yeung; Qi Chang; Yu Huang; Zhen-Yu Chen
Journal:  Br J Nutr       Date:  2004-06       Impact factor: 3.718

10.  Activation of peripheral delta2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury Involvement of protein kinase C, NO-synthase, KATP channels and the autonomic nervous system.

Authors:  Leonid N Maslov; Yury B Lishmanov; Peter R Oeltgen; Eva I Barzakh; Andrey V Krylatov; Meera Govindaswami; Stephen A Brown
Journal:  Life Sci       Date:  2009-02-24       Impact factor: 5.037

View more
  17 in total

1.  Epicatechin regulation of mitochondrial structure and function is opioid receptor dependent.

Authors:  Mathivadhani Panneerselvam; Sameh S Ali; J Cameron Finley; Sarah E Kellerhals; Michael Y Migita; Brian P Head; Piyush M Patel; David M Roth; Hemal H Patel
Journal:  Mol Nutr Food Res       Date:  2013-04-27       Impact factor: 5.914

2.  (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle.

Authors:  Leonardo Nogueira; Israel Ramirez-Sanchez; Guy A Perkins; Anne Murphy; Pam R Taub; Guillermo Ceballos; Francisco J Villarreal; Michael C Hogan; Moh H Malek
Journal:  J Physiol       Date:  2011-07-25       Impact factor: 5.182

Review 3.  Chocolate and coronary heart disease: a systematic review.

Authors:  Owais Khawaja; J Michael Gaziano; Luc Djoussé
Journal:  Curr Atheroscler Rep       Date:  2011-12       Impact factor: 5.113

Review 4.  ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.

Authors:  Ezequiel J Hid; Juana I Mosele; Paula D Prince; Cesar G Fraga; Monica Galleano
Journal:  Pflugers Arch       Date:  2021-11-23       Impact factor: 3.657

Review 5.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

6.  Synthesis of novel (-)-epicatechin derivatives as potential endothelial GPER agonists: Evaluation of biological effects.

Authors:  Viviana Sarmiento; Israel Ramirez-Sanchez; Aldo Moreno-Ulloa; Diego Romero-Perez; Daniel Chávez; Miguel Ortiz; Nayelli Najera; Jose Correa-Basurto; Francisco Villarreal; Guillermo Ceballos
Journal:  Bioorg Med Chem Lett       Date:  2018-01-24       Impact factor: 2.823

7.  Epicatechin's cardiovascular protective effects are mediated via opioid receptors and nitric oxide.

Authors:  Kirsty MacRae; Kylie Connolly; Rebecca Vella; Andrew Fenning
Journal:  Eur J Nutr       Date:  2018-05-10       Impact factor: 5.614

Review 8.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

9.  The effect of flavanol-rich cocoa on cerebral perfusion in healthy older adults during conscious resting state: a placebo controlled, crossover, acute trial.

Authors:  Daniel J Lamport; Deepa Pal; Christina Moutsiana; David T Field; Claire M Williams; Jeremy P E Spencer; Laurie T Butler
Journal:  Psychopharmacology (Berl)       Date:  2015-06-07       Impact factor: 4.530

Review 10.  Regulation of Cytochrome c Oxidase by Natural Compounds Resveratrol, (-)-Epicatechin, and Betaine.

Authors:  Icksoo Lee
Journal:  Cells       Date:  2021-05-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.